Bristol, Ambrx team up to develop antibody-based cancer drugs

05/6/2013 | Genetic Engineering & Biotechnology News

Bristol-Myers Squibb and Ambrx agreed to co-develop antibody drug conjugates for cancer with the latter's protein medicinal technology. Ambrx will receive $15 million upfront and as much as $97 million in research funding and milestone fees for each product, plus sales royalties. Bristol will get the global rights to develop and market the drugs arising from the partnership.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park